Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Cardiology
Volume 2016 (2016), Article ID 2343691, 6 pages
http://dx.doi.org/10.1155/2016/2343691
Case Report

Adult ADHD Medications and Their Cardiovascular Implications

1Division of Cardiology, Saint Luke’s University Health Network, 801 Ostrum Street, Bethlehem, PA 18015, USA
2Division of Pulmonary Medicine, Department of Internal Medicine, Howard University Hospital, 2041 Georgia Avenue, Washington, DC 20060, USA
3Department of Internal Medicine, Howard University Hospital, 2041 Georgia Avenue, Washington, DC 20060, USA
4Division of Hematology & Oncology, Department of Internal Medicine, Howard University Hospital, 2041 Georgia Avenue, Washington, DC 20060, USA
5Division of Cardiology, Howard University Hospital, 2041 Georgia Avenue, Washington, DC 20060, USA

Received 5 April 2016; Accepted 11 July 2016

Academic Editor: Magnus Baumhäkel

Copyright © 2016 A. Sinha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Kessler, L. Adler, R. Berkley et al., “The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication,” American Journal of Psychiatry, vol. 163, no. 4, pp. 716–723, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. Medco 2011 America's State of Mind, http://apps.who.int/medicinedocs/en/d/Js19032en/.
  3. T. Gerhard, A. G. Winterstein, M. Olfson, C. Huang, A. Saidi, and S. Crystal, “Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 5, pp. 457–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. T. E. Wilens, M. Martelon, G. Joshi et al., “Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 50, no. 6, pp. 543–553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Matthies, S. Holzner, B. Feige et al., “ADHD as a serious risk factor for early smoking and nicotine dependence in adulthood,” Journal of Attention Disorders, vol. 17, no. 3, pp. 176–186, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Castle, R. E. Aubert, R. R. Verbrugge, M. Khalid, and R. S. Epstein, “Trends in medication treatment for ADHD,” Journal of Attention Disorders, vol. 10, no. 4, pp. 335–342, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Sinha, O. Lewis, R. Kumar, S. L. Yeruva, and B. H. Curry, “Amphetamine abuse related acute myocardial infarction,” Case Reports in Cardiology, vol. 2016, Article ID 7967851, 6 pages, 2016. View at Publisher · View at Google Scholar
  8. P. J. Gandhi, G. U. Ezeala, T. T. Luyen, T. C. Tu, and M. T. Tran, “Myocardial infarction in an adolescent taking Adderall,” American Journal of Health-System Pharmacy, vol. 62, no. 14, pp. 1494–1497, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Biederman, E. Mick, C. Surman et al., “A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder,” Biological Psychiatry, vol. 59, no. 9, pp. 829–835, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Kaye, R. McKetin, J. Duflou, and S. Darke, “Methamphetamine and cardiovascular pathology: a review of the evidence,” Addiction, vol. 102, no. 8, pp. 1204–1211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. J. B. Treweek, T. J. Dickerson, and K. D. Janda, “Drugs of abuse that mediate advanced glycation end product formation: a chemical link to disease pathology,” Accounts of Chemical Research, vol. 42, no. 5, pp. 659–669, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Haning and D. Goebert, “Electrocardiographic abnormalities in methamphetamine abusers,” Addiction, vol. 102, supplement 1, pp. 70–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. D. Cohle, “Fatal coronary artery intimal hyperplasia due to amphetamine use,” Cardiovascular Pathology, vol. 22, no. 3, pp. e1–e4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. A. I. Qureshi, M. F. K. Suri, J. F. Kirmani, A. A. Divani, and Y. Mohammad, “Is prehypertension a risk factor for cardiovascular diseases?” Stroke, vol. 36, no. 9, pp. 1859–1863, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. R. S. Vasan, M. G. Larson, E. P. Leip et al., “Impact of high-normal blood pressure on the risk of cardiovascular disease,” The New England Journal of Medicine, vol. 345, no. 18, pp. 1291–1297, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. M. T. Cooney, E. Vartiainen, T. Laakitainen, A. Juolevi, A. Dudina, and I. M. Graham, “Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women,” American Heart Journal, vol. 159, no. 4, pp. 612–619.e3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Perret-Guillaume, L. Joly, and A. Benetos, “Heart rate as a risk factor for cardiovascular disease,” Progress in Cardiovascular Diseases, vol. 52, no. 1, pp. 6–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Mick, D. D. McManus, and R. J. Goldberg, “Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults,” European Neuropsychopharmacology, vol. 23, no. 6, pp. 534–541, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Hozawa, T. Ohkubo, M. Kikuya et al., “Prognostic value of home heart rate for cardiovascular mortality in the general population: the ohasama study,” American Journal of Hypertension, vol. 17, no. 11, pp. 1005–1010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Fox, I. Ford, P. G. Steg, M. Tendera, M. Robertson, and R. Ferrari, “Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial,” The Lancet, vol. 372, no. 9641, pp. 817–821, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. T. E. Wilens, P. G. Hammerness, J. Biederman et al., “Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder,” The Journal of Clinical Psychiatry, vol. 66, no. 2, pp. 253–259, 2005. View at Publisher · View at Google Scholar
  22. A. Ghuran and J. Nolan, “The cardiac complications of recreational drug use,” Western Journal of Medicine, vol. 173, no. 6, pp. 412–415, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Wehber and J. Hirsh, “New onset atrial fibrillation after initiating amphetamine-dextroamphetamine therapy for ADHD: a case report,” Case Reports in Internal Medicine, vol. 3, no. 1, 2015. View at Publisher · View at Google Scholar
  24. M. Mugmon, “Atrial flutter with aberrant conduction in a patient taking amphetamine salts and caffeine,” Journal of Community Hospital Internal Medicine Perspectives, vol. 1, no. 4, article 10663, 2012. View at Publisher · View at Google Scholar
  25. S. Ju-Young, L. Roughead, B.-J. Park, and N. Pratt, “Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study,” The British Medical Journal, vol. 353, p. i2550, 2016. View at Publisher · View at Google Scholar
  26. N. Oskooilar, “A case of premature ventricular contractions with modafinil,” The American Journal of Psychiatry, vol. 162, no. 10, pp. 1983–1984, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Zhang, V. Kutyifa, A. J. Moss, S. Mcnitt, W. Zareba, and E. S. Kaufman, “Long-QT syndrome and therapy for attention deficit/hyperactivity disorder,” Journal of Cardiovascular Electrophysiology, vol. 26, no. 10, pp. 1039–1044, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. C. N. Holick, B. R. Turnbull, M. E. Jones, S. Chaudhry, M. E. Bangs, and J. D. Seeger, “Atomoxetine and cerebrovascular outcomes in adults,” Journal of Clinical Psychopharmacology, vol. 29, no. 5, pp. 453–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Schelleman, W. B. Bilker, S. E. Kimmel et al., “Methylphenidate and risk of serious cardiovascular events in adults,” American Journal of Psychiatry, vol. 169, no. 2, pp. 178–185, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. L. A. Habel, W. O. Cooper, C. M. Sox et al., “ADHD medications and risk of serious cardiovascular events in young and middle-aged adults,” The Journal of the American Medical Association, vol. 306, no. 24, pp. 2673–2683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S. McCarthy, N. Cranswick, L. Potts, E. Taylor, and I. C. K. Wong, “Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database,” Drug Safety, vol. 32, no. 11, pp. 1089–1096, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. W. O. Cooper, L. A. Habel, C. M. Sox et al., “ADHD drugs and serious cardiovascular events in children and young adults,” The New England Journal of Medicine, vol. 365, no. 20, pp. 1896–1904, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Perrin, R. A. Friedman, T. K. Knilans et al., “Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder,” Pediatrics, vol. 122, no. 2, pp. 451–453, 2008. View at Publisher · View at Google Scholar
  34. P. Denchev, J. R. Kaltman, M. Schoenbaum, and B. Vitiello, “Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder,” Circulation, vol. 121, no. 11, pp. 1329–1337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. A. Adler, B. Zimmerman, H. L. Starr et al., “Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study,” Journal of Clinical Psychopharmacology, vol. 29, no. 3, pp. 239–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. V. L. Vetter, J. Elia, C. Erickson et al., “Cardiovascular monitoring of children and adolescents with heart disease receiving medication for ADHD: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,” Circulation, vol. 117, no. 8, pp. 2407–2423, 2008. View at Google Scholar
  37. R. Weathermon and D. W. Crabb, “Alcohol and medication interactions,” Alcohol Research and Health, vol. 23, no. 1, pp. 40–54, 1999. View at Google Scholar · View at Scopus
  38. D. M. Tomkins, S. V. Otton, N. Joharchi et al., “Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine,” Behavioural Pharmacology, vol. 8, no. 2-3, pp. 223–235, 1997. View at Google Scholar · View at Scopus